Ovarian premature failure (POF), also known as premature ovarian insufficiency (POI), refers to the loss of normal ovarian function in women before the age of 40, characterized by premature depletion of ovarian follicles or cessation of follicular development. POF is characterized by low levels of hormones and high levels of gonadotropins. Approximately 1% of women under the age of 40 and 0.1% of women under the age of 30 experience this condition. Clinical symptoms include irregular menstrual periods, difficult childbirth, hot flashes, night sweats, vaginal dryness, irritability, and concentration difficulties. The causes of POF include possible chromosomal defects, toxin exposure, and autoimmune diseases, but in most cases, the etiology remains unknown. For reproductive age women with cancer, damage to gonadal function from chemotherapy and radiation therapy is an important cause of POF. Therefore, POF treatment is beneficial for restoring fertility and maintaining menstrual cycles. Traditional chemotherapy drugs, cyclophosphamide (CTX) and busulfan (BU), are commonly used to construct POF animal models based on their severe reproductive toxicity levels.
The resveratrol cas no is 501-36-0. Resveratrol (RES) cas 501-36-0 is a natural plant toxin that is widely found in grapes, mulberries, and other plants. It can mediate various pharmacological effects, including anti-tumor, immunoregulatory, anti-inflammatory, antioxidant, cell protection, and anti-apoptotic effects. Accumulation of dysfunctional follicles related to the ovary can exacerbate the aging process. Resveratrol cas can effectively clear ROS accumulation. After removing excess ROS in the ovaries of Sprague-Dawley mice, follicular cells were found to not have cisplatin oxidative toxicity. In addition, RES can also improve follicular structure by reducing LH, LH/FSH ratio, and TNF-α levels. The above studies suggest that RES may improve premature ovarian failure by improving the environment of follicles and fgcs, thereby promoting their survival.
Two doses of resveratrol cas 501-36-0 (20mg/kg and 40mg/kg) were administered by gavage for 28 days. Then, the mouse weight, ovary weight, and ovary/mouse relative weight were calculated separately. The results showed that compared with the control group, the weight of POF mice decreased significantly, while the weight of mice in the 20mg/kg and 40mg/kg RES groups was higher than that in the POF group. We also calculated the total weight of mice every week. POF model mice had a slow growth rate, but the resveratrol cas 501-36-0 group had a faster growth rate. Although HE staining showed that the number of follicles in the RES-treated group was less than that in normal ovaries of mice, follicles of all levels were observed in the 20 and 40 mg/kg resveratrol cas treatment groups, but few
follicles were found in the POF group. Calculation of the number of follicles in each stage showed that the ratio of primary follicles to original follicles increased in the RES-treated group compared with the POF group. After treatment with resveratrol cas, the number or ratio of blocked follicles decreased, especially in the 40mg/kg RES group, and the ratio of original follicles increased gradually with increasing RES concentration compared with the POF group. In addition, the expression levels of the germinal system or stem-specific markers Muh and Oct4 in the RES group were significantly restored compared with the POF group, indicating that RES has a protective effect on the number and development of follicles in POF mice.